Physician profile
Sangeeta C Logani
NPI 1578676300
$4,623.83
in general payments reported to CMS, 2019-2025
23 companies · $809 in 2025
The $809 reported for 2025 was more than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $706 · 2021: $686 · 2022: $396 · 2023: $732 · 2024: $762 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,303.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $923.06 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $838.31 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $365.42 | 2024-2025 | Xdemvy |
| Galderma Laboratories, L.P. | $306.25 | 2019-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $256.23 | 2020-2021 | |
| Abbvie INC. | $236.84 | 2024-2025 | |
| Allergan, INC. | $230.81 | 2019-2021 | |
| Biotissue Holdings INC. | $226.13 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $186.02 | 2023-2024 | Xiidra, Miebo, Vyzulta |
| Amgen INC. | $172.69 | 2024-2025 | Tepezza |
| Glaukos Corporation | $158.10 | 2019-2020 | |
| Sight Sciences, INC. | $136.26 | 2020-2021 | |
| Alcon Vision LLC | $101.64 | 2020-2024 | Rocklatan, Eysuvis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $92.99 | 2020 | |
| Quidel Corporation | $91.64 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $85.34 | 2022-2023 | Tepezza |
| Oyster Point Pharma, INC. | $58.80 | 2022-2023 | Tyrvaya |
| Shire North American Group INC | $38.97 | 2019 | |
| Dompe US, INC. | $35.48 | 2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $22.72 | 2022 | |
| Harrow Eye, LLC | $22.65 | 2024 | Vevye |
| Tearlab Corp | $22.37 | 2023 | Tearlab Osmolarity System |
| Thea Pharma INC. | $15.11 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sangeeta Logani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.